Interferon alfa-2a vs Conventional Chemotherapy in Chronic Myeloid Leukemia
Interferon alfa-2a prolongs survival compared to conventional chemotherapy in patients with Philadelphia chromosome‑positive chronic myeloid leukemia.
This prospective, controlled trial compared recombinant interferon alfa-2a with conventional chemotherapy (hydroxyurea or busulfan) in Philadelphia chromosome–positive chronic myeloid leukemia. Among 322 randomized patients, interferon induced a higher karyotypic response rate (30% vs 5%) and prolonged time to progression and overall survival (median 72 vs 52 months; 6‑year survival 50% vs 29%). Both regimens were associated with treatment‑related deaths; interferon caused dose‑relieving side effects in 16% of patients.
The study demonstrates interferon alfa-2a as a viable alternative to conventional chemotherapy for newly diagnosed or minimally treated chronic myeloid leukemia, offering improved survival and a manageable safety profile relative to cyclophosphamide‑like agents.
Bizonyítékszint: Számítógépes vagy elméleti. Modellből vagy adatbányászatból származó jel.
Kapcsolódó jelek
- Treatment of chronic myeloid leukemia chronic phase patients in third-line setting and beyond: recommendations from a Belgian expert panel in 2025
- Chronic myeloid leukemia: Current guidelines for diagnosis and management
- Nilotinib versus imatinib with early switch from imatinib to nilotinib to obtain treatment‑free remission in newly diagnosed chronic myeloid leukemia patients: the analysis of the first co‑primary endpoint
- Information about Project 4: Chronic myeloid leukemia (CML)
- Prevalence and characterization of germline RAS pathway variants in children with chronic myeloid leukemia